|
|
|
|
Direct Cost |
Indirect Cost |
|
261201000004C-11-0-1 |
THE NATIONAL CANCER INSTITUTE'S CONTACT CENTER |
FRED HUTCHINSON CAN RES CTR |
NCI |
|
|
$6,537,257 |
261201300012I-0-26100001-1 |
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM |
FRED HUTCHINSON CAN RES CTR |
NCI |
|
|
$3,212,212 |
261201300012I-0-26100002-1 |
Patterns of Care/Quality of Care - Diagnosis Year 2012 |
FRED HUTCHINSON CAN RES CTR |
NCI |
|
|
$65,720 |
268201100046C-4-0-1 |
BIOMEDICAL (BASIC) |
FRED HUTCHINSON CAN RES CTR |
NHLBI |
|
|
$9,995,351 |
268201300007C-0-0-1 |
IGF::OT::IGF LEUKOCYTE TELOMERE DYNAMICS, CARDIOVASCULAR AGING AND SURVIVAL IN T |
FRED HUTCHINSON CAN RES CTR |
NHLBI |
|
|
$678,101 |
1F32CA174277-01A1 |
Exploiting the Genomic Programs Underlying AR-Independent Prostate Cancer |
FRED HUTCHINSON CAN RES CTR |
NCI |
$52,190 |
|
$52,190 |
1K07CA172298-01 |
Lifestyle Factors and Survival Outcomes for Colorectal Cancer Molecular Subtypes |
FRED HUTCHINSON CAN RES CTR |
NCI |
$115,959 |
$9,277 |
$125,236 |
1K08CA169485-01A1 |
Targeting Leukemia with Memory CD8+ T cells Transduced to Express High-Affinity W |
FRED HUTCHINSON CAN RES CTR |
NCI |
$158,678 |
$12,694 |
$171,372 |
1K23CA154874-01A1 |
Optimization of adoptive immunotherapy with autologous CD20-specific T cells |
FRED HUTCHINSON CAN RES CTR |
NCI |
$159,000 |
$12,720 |
$171,720 |
1K23CA175167-01 |
Adoptive T cell Therapy for Patients with NY-ESO-1 Expressing Sarcomas |
FRED HUTCHINSON CAN RES CTR |
NCI |
$159,000 |
$12,720 |
$171,720 |
1K99AG043095-01A1 |
Role of Mitophagy in Mitochondrial Protein Quality Control |
FRED HUTCHINSON CAN RES CTR |
NIA |
$83,333 |
$6,667 |
$90,000 |
1K99GM107351-01 |
Evolutionary and functional diversification of chromatin proteins |
FRED HUTCHINSON CAN RES CTR |
NIGMS |
$83,333 |
$6,667 |
$90,000 |
1K99NS085035-01 |
Molecular mechanisms of electrical synapse formation in vivo |
FRED HUTCHINSON CAN RES CTR |
NINDS |
$83,333 |
$6,667 |
$90,000 |
1R01CA166646-01A1 |
Randomized Trial of Web-Delivered Acceptance Therapy for Smoking Cessation |
FRED HUTCHINSON CAN RES CTR |
NCI |
$430,859 |
$314,310 |
$745,169 |
1R01CA168338-01A1 |
A Cohort Study of Sessile Serrated Polyps and Subsequent Colorectal Neoplasia |
FRED HUTCHINSON CAN RES CTR |
NCI |
$528,628 |
$139,494 |
$668,122 |
1R01CA168758-01A1 |
Epidemiologic factors and survival by molecular subtypes of ovarian cancer |
FRED HUTCHINSON CAN RES CTR |
NCI |
$448,237 |
$234,425 |
$682,662 |
1R01CA172415-01A1 |
Methods for Time-Varying Disease Attribution in Chronic Disease Prevention |
FRED HUTCHINSON CAN RES CTR |
NCI |
$207,500 |
$147,751 |
$355,251 |
1R01CA172582-01 |
Alpha Radioimmunotherapy for Lymphoma Treatment |
FRED HUTCHINSON CAN RES CTR |
NCI |
$442,983 |
$236,406 |
$679,389 |
1R01CA175008-01A1 |
The Genetics of Post-Transplant Relapse in Myeloid Malignancy |
FRED HUTCHINSON CAN RES CTR |
NCI |
$207,500 |
$157,700 |
$365,200 |
1R01CA175215-01 |
Single-Cell Methods for Analysis of Clonal Heterogeneity and Evolution in Cancer |
FRED HUTCHINSON CAN RES CTR |
NCI |
$437,266 |
$209,220 |
$646,486 |